期刊文献+

弥漫大B细胞淋巴瘤预后相关因素研究进展 被引量:13

下载PDF
导出
摘要 弥漫大B细胞淋巴瘤(DLBCL)是一组在临床表现、组织形态多方面具有很大异质性的恶性肿瘤,根据相关不良预后可早期识别出高危患者,有效提高患者生存率。因而,如何准确地判断患者预后成为目前研究的热点。本文作者就DLBCL的预后评分系统的演化、分子因素及其他相关评估因素进行综述。
作者 李岩 刘爱春
出处 《东南大学学报(医学版)》 CAS 北大核心 2017年第4期666-670,共5页 Journal of Southeast University(Medical Science Edition)
基金 国家自然科学基金资助项目(81070684)
  • 相关文献

参考文献10

二级参考文献137

  • 1Casares S,Ionov Y,Ge HY,et al.The microsatelit mutator phenotype of colon cancer cells is often recessive.oncongene[J].1995,11(11):2303-2310.
  • 2Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications [ J ]. Blood, 2011,117 ( 19 ) : 5019-5032.
  • 3Li JM, Wang L, Shen Y, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients [ J ]. Ann Hematol, 2007, 86 ( 9 ) : 639-645.
  • 4Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[ J 3. N Engl J Med, 2002, 346 (4) : 235 -242.
  • 5Coiffier B, Thieblemont C, Van Deneste E, et al. Long-term outcome of patients in the LNH-98. 5 trial, the firstrandomized study comparing rituximab-CHOP to standard CHOP chemotherapyin DLBCLpafients:astudyby the Groupe d'Etudes des T.vmnhnm,rlo lrAcl,,hol- T3 RIA filN 11g/1")' '3NAN "Ar.
  • 6Habermann TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenancerituximab in older patients with diffuse large B-cell lymphoma [ J ]. J Clin Oncol, 2006, 24(19) :3121-3127.
  • 7Pfreundschuh M, Kuhnt E, Tramper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomisedstudy of theMabThera International Trial (MINT) Group[ J]. Lancet Oncol, 2011, 12( 11 ) : 1013-1022.
  • 8Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patientswith aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60) [ J ]. Lancet Oncol, 2008, 9(2) :105-116.
  • 9Pfreundschuh M, Tramper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MINT) Group [ J ]. Lancet Oncol, 2006, 7 ( " . Z7O -RQ 1.
  • 10Farinha P, Masoudi H, Skinnider BF, et al. Analyis of multiple biomarkers shows that lymphoma-associated macrophages (LAM) content is an independent predictor of survival in follicular lymphoma[ J]. Blood,2005,106(6) :2169-2174.

共引文献59

同被引文献92

引证文献13

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部